Research programme: stem cell modulators - Intrexon/Superview Biotechnology

Drug Profile

Research programme: stem cell modulators - Intrexon/Superview Biotechnology

Latest Information Update: 12 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediStem Laboratories; Superview Biotechnology
  • Developer Medistem; Superview Biotechnology
  • Class Monoclonal antibodies
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 12 Mar 2014 No development reported for Undefined indication (unspecified route)
  • 07 Mar 2014 Medistem has been acquired by Intrexon Corporation
  • 01 Oct 2012 Early research in Undefined indication (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top